^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + oleclumab (MEDI9447) (CD73 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Excerpt:
...- Have histologic or cytologic documentation of solid tumor including EGFR mutated (EGFRm) NSCLC...
Source:
Title:
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Published date:
04/05/2023
Excerpt:
Patients received oleclumab 5–40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W), alone (escalation only) or with durvalumab 10 mg/kg intravenously Q2W....192 patients were enrolled into 4 monotherapy (n = 42) and 4 combination therapy (n = 24) escalation cohorts ....In the EGFRm NSCLC expansion cohort, 4 patients (9.5%) had PRs, with a median DoR of 14.8 months (range, 5.6–24.0; 1 response ongoing) (Fig. 4c). An additional 9 patients (21.4%) had SD ≥ 8 weeks. Overall, DC was ≥ 24 weeks in 6 (14.3%) patients.
DOI:
10.1007/s00262-023-03430-6
Trial ID:
Source:
Title:
Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC)
Published date:
05/19/2021
Excerpt:
ORs were seen in...4 EGFRm NSCLC pts (DoR range 5.6 to 15.7+ mos)...9 EGFRm NSCLC pts had SD….Oleclumab ± durvalumab had a tolerable safety profile and combination therapy showed promising antitumor activity in EGFRm NSCLC.
DOI:
10.1200/JCO.2021.39.15_suppl.9047
Trial ID:
Source:
Title:
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Published date:
02/08/2022
Excerpt:
...we developed an EGFR-mutated NSCLC mouse model using genetically modified HCC2935 and PC9 cells....Mice were then treated with an isotype control antibody, anti–PD-L1 (MEDI4736, durvalumab) (4), anti-CD73 (MEDI9447, oleclumab), or a combination of anti–PD-L1 and anti-CD73 (durvalumab/oleclumab) (Figure 4A)…. mice treated with a combination of durvalumab and oleclumab had significantly smaller tumors compared with mice in other groups (Figure 4B). Furthermore, tumor growth was much lower in mice treated with the antibody combination when tumor volumes at the start and end of treatment were compared (Figure 4C).
DOI:
10.1172/jci.insight.142843
